Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab

Stock Information for Tiziana Life Sciences Ltd

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Tiziana Life Sciences Ltd

Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman
Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial
Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman
Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York
Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial
Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis
Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab
Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.